- Home
- ARGX vs ZBH Comparison
ARGX vs ZBH Comparison
Compare ARGX & ZBH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ARGX
- ZBH
- Stock Information
- Founded
- ARGX 2008
- ZBH 1927
- Country
- ARGX Netherlands
- ZBH United States
- Employees
- ARGX N/A
- ZBH 17000
- Industry
- ARGX Biotechnology: Biological Products (No Diagnostic Substances)
- ZBH Industrial Specialties
- Sector
- ARGX Health Care
- ZBH Health Care
- Exchange
- ARGX Nasdaq
- ZBH Nasdaq
- Market Cap
- ARGX 44.2B
- ZBH 20.0B
- IPO Year
- ARGX 2017
- ZBH N/A
- Fundamental
- Price
- ARGX $750.56
- ZBH $99.73
- Analyst Decision
- ARGX Strong Buy
- ZBH Buy
- Analyst Count
- ARGX 19
- ZBH 18
- Target Price
- ARGX $777.83
- ZBH $112.00
- AVG Volume (30 Days)
- ARGX 360.8K
- ZBH 1.2M
- Earning Date
- ARGX 10-30-2025
- ZBH 10-29-2025
- Dividend Yield
- ARGX N/A
- ZBH 0.95%
- EPS Growth
- ARGX N/A
- ZBH N/A
- EPS
- ARGX 18.75
- ZBH 4.11
- Revenue
- ARGX $3,120,821,000.00
- ZBH $7,833,800,000.00
- Revenue This Year
- ARGX $80.01
- ZBH $8.20
- Revenue Next Year
- ARGX $30.64
- ZBH $5.93
- P/E Ratio
- ARGX $35.87
- ZBH $24.56
- Revenue Growth
- ARGX 88.04
- ZBH 4.11
- 52 Week Low
- ARGX $510.06
- ZBH $89.22
- 52 Week High
- ARGX $779.03
- ZBH $114.72
- Technical
- Relative Strength Index (RSI)
- ARGX 70.97
- ZBH 51.02
- Support Level
- ARGX $745.91
- ZBH N/A
- Resistance Level
- ARGX $779.03
- ZBH $104.49
- Average True Range (ATR)
- ARGX 14.74
- ZBH 1.56
- MACD
- ARGX -0.14
- ZBH -4.65
- Stochastic Oscillator
- ARGX 66.50
- ZBH 92.47
About ARGX argenx SE
Argenx is a Dutch biopharmaceutical company focused on developing antibody-based therapies for rare autoimmune diseases. The company's lead product, Vyvgart (efgartigimod), was approved by the FDA in December 2021 for the treatment of generalized myasthenia gravis (gMG). In 2022, Argenx also received FDA approval for Vyvgart Hytrulo, a subcutaneous formulation of Vyvgart, offering a more convenient option compared with Vyvgart's intravenous administration. In 2024, the FDA approved Vyvgart Hytrulo for Chronic Inflammatory Demyelinating Polyneuropathy, a rare immune-mediated neuromuscular disorder of the peripheral nervous system. Argenx is focused on innovation and developing its pipeline for treatments such as primary immune thrombocytopenia, thyroid eye disease, and Sjogren's Disease.
About ZBH Zimmer Biomet Holdings Inc.
Zimmer Biomet designs, manufactures, and markets orthopedic reconstructive implants as well as supplies and surgical equipment for orthopedic surgery. With the acquisitions of Centerpulse in 2003 and Biomet in 2015, Zimmer holds the leading share of the reconstructive market in the United States, Europe, and Japan. Roughly two-thirds of total revenue is derived from sales of large joints; another fourth comes from extremities, trauma, sports medicine, and related surgical products. The firm spun out its dental and spine businesses in 2022.